NEOK Bio is a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) that are designed to improve outcomes for cancer patients. NEOK is rapidly advancing bispecific ADCs which represent a cutting-edge advancement, leveraging bispecific antibodies that target two complimentary antigens, potentially improving safety while enhancing the efficacy of ADCs in a wider range of tumors. Backed by ABL Bio, Inc., a proven leader in antibody engineering, NEOK plans to initiate clinical studies for its two lead bispecific ADC candidates in solid tumor indications in mid-2026.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/04/25 | $75,000,000 | Series A |
ABL Bio | undisclosed |
